A5065937767- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Genomics and Rare Diseases
- Protein Degradation and Inhibitors
- PARP inhibition in cancer therapy
- Cancer Mechanisms and Therapy
- Palliative Care and End-of-Life Issues
- Cutaneous lymphoproliferative disorders research
- Sarcoma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Liver Disease Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Family Support in Illness
- Genetic factors in colorectal cancer
- Family and Patient Care in Intensive Care Units
- Fungal Infections and Studies
- Colorectal and Anal Carcinomas
- Lung Cancer Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
Christian Medical College & Hospital
2024
Meenakshi Mission Hospital and Research Centre
2021-2024
Abstract Background The integration of next-generation sequencing (NGS) in guiding personalized therapy for oncology faces the challenges, primarily, cost and drug accessibility. Limited data from Indian academic centers accentuate need comprehensive insights into real-world applications NGS oncology. Methods Network Oncology Clinical Trials India (NOCI), accessible at www.noci-india.com, compiled on patients who underwent solid organ cancers January 1, 2018, to December 31, 2021. This study...
The incidence of periampullary tumours has been on the rise in India. Although significant advances have made diagnostic and treatment modalities, they remain one which eludes early diagnosis owing to lack screening tests. This is compounded by a complex surgical procedure only modality with curative intent. Focussed perioperative care can effect improving positive patient outcomes. article outlines disease, options such as biliary drainage, surgery clinical guidelines period, would enable...
Abstract Multiple myeloma (MM) accounts for ∼10% of total hematologic malignancies worldwide. In India, the incidence MM has increased two-fold with marked heterogeneity. Significant improvements in terms clinical outcomes have been observed management recent years. However, most patients develop a disease relapse first or subsequent treatments. A combination immunomodulatory drugs (thalidomide and lenalidomide) proteasome inhibitors (PIs; bortezomib) mainstay therapeutic relapsed/refractory...
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic for which there are no effective therapies. We present 70-year-old male patient with multiple reddish painless, nonpruritic, and nonpedunculated nodules over the trunk, forearm, thighs duration of 3 months. The measured 0.5 to 2 cm in diameter. peripheral smear findings were within normal limits. Excision biopsy was performed. Histomorphology immunohistochemistry (CD123, CD 56, CD4, HLA-DR, CD43, CD68)...